Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

Adverum Presents 2-Year OPTIC Data Demonstrating Sustained Durability And Promising Safety Profile From Single Intravitreal Injection Of ADVM-022 In Wet AMD Patients Who Previously Required Frequent Anti-VEGF Injections

REDWOOD CITY, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today

ADVM